Sana Biotechnology, Inc. SANA
Sana Biotechnology, Inc. (Nasdaq: SANA) is an endocrine/women's health drug developer. Its lead program, SC451, is in Pre-clinical for type 1 diabetes. Its next catalyst on record is SC451: IND filing and begin Phase 1/2 clinical trial (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SC451 — IND filing and begin Phase 1/2 clinical trial (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SC451 (HIP-edited stem cell-derived islet cells) | type 1 diabetes | cell therapy | Pre-clinical |
| SG293 (in vivo CD8-targeted CD19 CAR T fusosome) | B cell malignancies (non-Hodgkin lymphoma) and B cell mediated autoimmune diseases | gene therapy | Pre-clinical |
| SG227 (in vivo CD8-targeted BCMA CAR T fusosome) | multiple myeloma | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.